Oncologic Pathologist at Caris Life Sciences, specializing in molecular cancer profiling and serving as the recognized pathology subject matter expert within R&D. My background includes board certification in anatomic, clinical, and molecular pathology, doctoral training in cancer research, and industry experience in analyzing drug discovery data as an informatics scientist.
2024 Number of Patient Cases Evaluated Per State in the Diagnosis and Treatment of Cancer
Education/Training
Fellowship – Memorial Sloan Kettering Cancer Center (New York, NY), Molecular Genetic Pathology – 2022-2023
Residency – Johns Hopkins Hospital (Baltimore, MD), Anatomic and Clinical Pathology – 2018-2022
Medical School – Indiana University School of Medicine (Indianapolis, IN), MD/PhD – 2010-2018
Publications
Clinical Bioinformatician Body of Knowledge – Bioinformatics and Software Knowledge Core: A Report of the Association for Molecular Pathology.
Kadri, S., Craven, K.E., Gee, E.P.S., Klee, E.W., Krumm, N., Zehir, A., Zhang, W., Sboner, A. (2025). J Mol Diag, 27(7) , 566-582.
Premalignant Clonal Hematopoiesis (Clonal Hematopoiesis of Indeterminate Potential and Clonal Cytopenia of Undetermined Significance).
Craven, K.E., Ewalt, M.D. (2023). Clin Lab Med, 43(4), 565-576.
Optimizing Insertion and Deletion Detection using Next Generation Sequencing in the Clinical Laboratory.
Craven, K.E., Fischer, C.G., Jiang, L., Pallavajjala, A., Lin, M.T., Eshleman, J.R. (2022). J Mol Diagn, 24(12), 1217-1231.
CIBERSORT Analysis of TCGA and METABRIC Identifies Subgroups with Better Outcomes in Triple Negative Breast Cancer.
Craven, K. E., Gökem-Polar, Y., Badve, S. S. (2021). Sci Rep, 11(1), 4691.
Rapidly progressive metastatic cholangiocarcinoma in a postpartum patient with cystic fibrosis: a case report.
Carson, S. W., Craven, K. E., Nauen, D., Montemayor, K., Yarchoan, M., Burns, W. R., Merlo, C. A., & West, N. E. (2020). BMC Pulm Med, 20(1), 298.
Overview of pre-clinical and clinical studies targeting angiogenesis in pancreatic ductal adenocarcinoma.
Craven, K. E., Gore, J., & Korc, M. (2016). Cancer Lett, 381(1), 201-210.
Combined targeting of TGF-beta, EGFR and HER2 suppresses lymphangiogenesis and metastasis in a pancreatic cancer model.
Gore, J., Imasuen-Williams, I. E., Conteh, A. M., Craven, K. E., Cheng, M., & Korc, M. (2016). Cancer Lett, 379(1), 143-153.
Angiogenic gene signature in human pancreatic cancer correlates with TGF-beta and inflammatory transcriptomes.
Craven, K. E., Gore, J., Wilson, J. L., & Korc, M. (2016). Oncotarget, 7(1), 323-341.
Integrated stress response is critical for gemcitabine resistance in pancreatic ductal adenocarcinoma.
Palam, L. R., Gore, J., Craven, K. E., Wilson, J. L., & Korc, M. (2015). Cell Death Dis, 6(10), e1913.
Organ-specific adaptive signaling pathway activation in metastatic breast cancer cells.
Burnett, R. M., Craven, K. E., Krishnamurthy, P., Goswami, C. P., Badve, S., Crooks, P., Mathews, W. P., Bhat-Nakshatri, P., & Nakshatri, H. (2015). Oncotarget, 6(14), 12682-12696.
TCGA data and patient-derived orthotopic xenografts highlight pancreatic cancer-associated angiogenesis.
Gore, J., Craven, K. E., Wilson, J. L., Cote, G. A., Cheng, M., Nguyen, H. V., Cramer, H. M., Sherman, S., & Korc, M. (2015). Oncotarget, 6(10), 7504-7521.
Pancreatic cancer-associated retinoblastoma 1 dysfunction enables TGF-beta to promote proliferation.
Gore, A. J., Deitz, S. L., Palam, L. R., Craven, K. E., & Korc, M. (2014). J Clin Invest, 124(1), 338-352.
Assessment of diet-induced obese rats as an obesity model by comparative functional genomics.
Li, S., Zhang, H. Y., Hu, C. C., Lawrence, F., Gallagher, K. E., Surapaneni, A., Estrem, S. T., Calley, J. N., Varga, G., Dow, E. R., & Chen, Y. (2008). Obesity (Silver Spring), 16(4), 811-818.